Literature DB >> 25736553

Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency.

Christopher Grunseich1, Alice B Schindler, Ke-Lian Chen, Dara Bakar, Ami Mankodi, Ryan Traslavina, Abhik Ray-Chaudhury, Tanya J Lehky, Eva H Baker, Nicholas J Maragakis, Cynthia J Tifft, Kenneth H Fischbeck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736553      PMCID: PMC4405612          DOI: 10.1007/s00415-015-7683-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
Dear Sirs, Sandhoff disease is a lysosomal storage disease caused by a deficiency of beta-hexosaminidase. Affected individuals present with a wide spectrum of clinical manifestations, ranging from psychomotor impairment and death in the infantile form to motor neuron disease and autonomic dysfunction in the adult form [1, 2]. Here, we present a family with predominantly sensory neuropathy that was found to have both Sandhoff disease and deficiency of SH3TC2. A 46-year-old man had weakness, atrophy, and paresthesia with loss of sensation in his hands and feet for 30 years (Fig. 1a). He also had severe diarrhea several times per week, decreased sweating over his feet, and episodes of lightheadedness. On examination, he was found to have marked upper and lower extremity weakness and muscle atrophy distally, with the legs more severely affected (Fig. 1b). Although hyperreflexia was found in the upper extremities, reflexes in the lower extremities were reduced. Electromyography showed evidence of chronic neurogenic changes, and nerve conduction studies showed normal motor conduction velocities (patient 40–67 m/s, sibling 39–58 m/s). However, sensory nerve conduction studies were non-responsive in the proband and either non-responsive or reduced in amplitude and velocity (41 m/s) in the sibling. Autonomic testing (QSWEAT, Heart Rate Response to Deep Breathing, Valsalva, Tilt Table) and quantitative sensory testing (Vibratory Detection Threshold and Cooling Detection Threshold) showed evidence of autonomic dysfunction consistent with a severe small unmyelinated fiber and large myelinated fiber sensory neuropathy (Fig. 1d) [3]. Laboratory testing for acquired causes of neuropathy was negative. An evaluation of the proband’s 57-year-old sister showed a similar pattern of sensory, motor, and autonomic involvement, with symptom onset in her 20s. Both individuals did not show evidence of macular abnormalities; however, mild splenomegaly was found in the sister (span 14.2 cm).
Fig. 1

Family pedigree and phenotypical evaluations in the proband. a Family pedigree. The arrow indicates the proband. Three of the proband’s sisters were also heterozygous for the SH3TC2 mutation, but only the two affected individuals had compound heterozygous mutations in HEXB and the SH3TC2 mutation. A paternal uncle was diagnosed with amyotrophic lateral sclerosis (ALS). b A photo of the proband showing atrophy and bluish discoloration of the feet. c MR spectroscopy (MRS) of the superior cerebellar vermis showing low N-acetylaspartate (NAA)/creatine ratio, low choline (Cho)/creatine (Cr) ratio, and normal choline/NAA ratio (the arrow indicates the elevated creatine peak). MRS of the same location in the proband’s affected sister showed a low choline/creatine ratio. Normal reference ranges were established from five controls. d The vibratory detection threshold (VDT) for the hand, showing increased detection threshold stimulus magnitude just noticeable difference (JND). Shaded circles indicate when a stimulus was detected. No stimulus was administered in trials 2, 4, 12, 14, and 18. The average threshold observed is 19.0 JND (red line), higher than the normative control average of 14.4 JND (blue line). e Hematoxylin and eosin (H+E) staining of the proband’s sural nerve demonstrating a reduction of large myelinated nerve fibers; bar 100 μm. f Staining with periodic acid–Schiff (PAS) (pink) and SH3TC2 (brown) in Schwann cells. Arrow indicates miniature onion bulb with multiple Schwann cell nuclei. g Luxol fast staining of a longitudinal section showing evidence of demyelination. h Gomori trichrome staining showing a reduction in myelin staining (red) in the patient as compared to control. i PAS staining in patient’s Schwann cells showing positive staining compared to control. j Staining with an antibody for SH3TC2 shows a reduction in staining in the patient compared to control. Bar 50 μm for (f–j)

Family pedigree and phenotypical evaluations in the proband. a Family pedigree. The arrow indicates the proband. Three of the proband’s sisters were also heterozygous for the SH3TC2 mutation, but only the two affected individuals had compound heterozygous mutations in HEXB and the SH3TC2 mutation. A paternal uncle was diagnosed with amyotrophic lateral sclerosis (ALS). b A photo of the proband showing atrophy and bluish discoloration of the feet. c MR spectroscopy (MRS) of the superior cerebellar vermis showing low N-acetylaspartate (NAA)/creatine ratio, low choline (Cho)/creatine (Cr) ratio, and normal choline/NAA ratio (the arrow indicates the elevated creatine peak). MRS of the same location in the proband’s affected sister showed a low choline/creatine ratio. Normal reference ranges were established from five controls. d The vibratory detection threshold (VDT) for the hand, showing increased detection threshold stimulus magnitude just noticeable difference (JND). Shaded circles indicate when a stimulus was detected. No stimulus was administered in trials 2, 4, 12, 14, and 18. The average threshold observed is 19.0 JND (red line), higher than the normative control average of 14.4 JND (blue line). e Hematoxylin and eosin (H+E) staining of the proband’s sural nerve demonstrating a reduction of large myelinated nerve fibers; bar 100 μm. f Staining with periodic acid–Schiff (PAS) (pink) and SH3TC2 (brown) in Schwann cells. Arrow indicates miniature onion bulb with multiple Schwann cell nuclei. g Luxol fast staining of a longitudinal section showing evidence of demyelination. h Gomori trichrome staining showing a reduction in myelin staining (red) in the patient as compared to control. i PAS staining in patient’s Schwann cells showing positive staining compared to control. j Staining with an antibody for SH3TC2 shows a reduction in staining in the patient compared to control. Bar 50 μm for (f–j) After negative genetic testing (Athena Diagnostics Inc.) of ten candidate neuropathy genes (PMP22, Cx32, MPZ, PMP22, EGR2, NFL, PRX, GDAP1, LITAF, MFN2), whole exome sequencing (NISC/NHGRI/NIH) of the proband identified a common 1250C>T mutation (P417L) in HEXB and a previously reported [4] 2860C>T mutation (R954X) in SH3TC2, which was confirmed by Sanger sequencing (GeneDx). Further testing through multiplex ligation-dependent probe amplification (MLPA, GeneDx) showed that the proband is also heterozygous for a 16-kb deletion that includes exons 1–5 of the HEXB gene. The three variants were also confirmed in the affected sister, and although two of the unaffected sisters were found to have the SH3TC2 mutation, neither have both HEXB mutations. MR spectroscopy of the superior cerebellar vermis detected elevated creatine in the proband (Fig. 1c). Serum testing in both affected siblings showed low total hexosaminidase activity of 1.4 and 1.0 nmol/min/mL (normal 10.4–23.8) and an increased fraction of HEXA activity at 91 and 100 % (normal 56–80 %). A sural nerve biopsy from the proband showed evidence of a severe mixed axonal and demyelinating neuropathy (Fig. 1e–i) and a reduction in SH3TC2 immunoreactivity (Fig. 1j). The adult form of beta-hexosaminidase deficiency is characterized by upper and lower motor neuron dysfunction, dysautonomia, and ataxia. The amino acid change in HEXB at position 417 is a common gene mutation in adult Sandhoff disease patients [5]. The early and severe presentation of sensory findings in both of these siblings is not a typical presentation of the disease [6-8]. The nonsense mutation observed in this family is predicted to reduce levels of SH3TC2, consistent with the pattern detected on peripheral nerve staining. Given the unusual presentation with pronounced sensory neuropathy in this HEXB family and the evidence of myelin defects on nerve biopsy, not explained by Sandhoff disease alone, it is plausible that the deficiency in SH3TC2 may be modifying the HEXB phenotype. SH3TC2 is localized to the endosome, and disease-causing missense mutations mistarget the protein away from this location and result in a demyelinating neuropathy [9]. It is possible that the accumulation of GM2 ganglioside in HEXB-deficient endosomes and lysosomes may be preferentially damaging to tissues that also have a deficiency of SH3TC2.
  9 in total

1.  A common beta hexosaminidase gene mutation in adult Sandhoff disease patients.

Authors:  M Gomez-Lira; A Sangalli; M Mottes; C Perusi; P F Pignatti; N Rizzuto; A Salviati
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

2.  Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy.

Authors:  James R Lupski; Jeffrey G Reid; Claudia Gonzaga-Jauregui; David Rio Deiros; David C Y Chen; Lynne Nazareth; Matthew Bainbridge; Huyen Dinh; Chyn Jing; David A Wheeler; Amy L McGuire; Feng Zhang; Pawel Stankiewicz; John J Halperin; Chengyong Yang; Curtis Gehman; Danwei Guo; Rola K Irikat; Warren Tom; Nick J Fantin; Donna M Muzny; Richard A Gibbs
Journal:  N Engl J Med       Date:  2010-03-10       Impact factor: 91.245

3.  New cases of adult-onset Sandhoff disease with a cerebellar or lower motor neuron phenotype.

Authors:  C C S Delnooz; D J Lefeber; S M C Langemeijer; S Hoffjan; G Dekomien; M J Zwarts; B G M Van Engelen; R A Wevers; H J Schelhaas; B P C van de Warrenburg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09       Impact factor: 10.154

4.  An unusual splicing mutation in the HEXB gene is associated with dramatically different phenotypes in patients from different racial backgrounds.

Authors:  B McInnes; M Potier; N Wakamatsu; S B Melancon; M H Klavins; S Tsuji; D J Mahuran
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold.

Authors:  P J Dyck; P C O'Brien; J L Kosanke; D A Gillen; J L Karnes
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

6.  Early and severe sensory loss in three adult siblings with hexosaminidase A and B deficiency (Sandhoff disease).

Authors:  H Schnorf; R Gitzelmann; N U Bosshard; M Spycher; W Waespe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

Review 7.  The lysosomal hexosaminidase isozymes.

Authors:  D Mahuran; A Novak; J A Lowden
Journal:  Isozymes Curr Top Biol Med Res       Date:  1985

8.  Adult onset motor neuronopathy in the juvenile type of hexosaminidase A and B deficiency.

Authors:  M Rubin; G Karpati; L S Wolfe; S Carpenter; M H Klavins; D J Mahuran
Journal:  J Neurol Sci       Date:  1988-10       Impact factor: 3.181

9.  Mistargeting of SH3TC2 away from the recycling endosome causes Charcot-Marie-Tooth disease type 4C.

Authors:  Rhys C Roberts; Andrew A Peden; Folma Buss; Nicholas A Bright; Morwena Latouche; Mary M Reilly; John Kendrick-Jones; J Paul Luzio
Journal:  Hum Mol Genet       Date:  2009-12-22       Impact factor: 6.150

  9 in total
  3 in total

1.  The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.

Authors:  Camilo Toro; Mosufa Zainab; Cynthia J Tifft
Journal:  Neurosci Lett       Date:  2021-08-25       Impact factor: 3.046

Review 2.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

3.  Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases.

Authors:  Christopher Grunseich; Nathan Sarkar; Joyce Lu; Mallory Owen; Alice Schindler; Peter A Calabresi; Charlotte J Sumner; Ricardo H Roda; Vinay Chaudhry; Thomas E Lloyd; Thomas O Crawford; S H Subramony; Shin J Oh; Perry Richardson; Kurenai Tanji; Justin Y Kwan; Kenneth H Fischbeck; Ami Mankodi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-06-08       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.